Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Howard Glick

Psychiatry Ashburn, VA Medical Doctor

NPI 1790798965 CMS profile 955188

21001 Sycolin Rd, Ashburn, VA 20147

Open in the dashboard

General payments

$2,882

137 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Howard Glick of Ashburn, VA is reported in the CMS Open Payments database as having received $2,882 across 137 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $24 1
2022 General $429 24
2021 General $186 9
2020 General $388 27
2019 General $1,856 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Glick
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Howard Glick were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Howard Glick Psychiatry median Middle half National median
2019 $1,856 $184 $59–$605 $163
2020 $388 $119 $36–$372 $114
2021 $186 $143 $43–$576 $132
2022 $429 $153 $50–$590 $149
2023 $24 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Supernus Pharmaceuticals, Inc. $931 28 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $357 19 payments
  3. Lundbeck LLC $309 18 payments
  4. Ironshore Pharmaceuticals Inc. $267 7 payments
  5. Otsuka America Pharmaceutical, Inc. $220 16 payments
  6. Neos Therapeutics, LP $188 14 payments
  7. Allergan Inc. $180 12 payments
  8. Alkermes, Inc. $90 1 payment
  9. Tris Pharma Inc $82 5 payments
  10. Shire North American Group Inc $64 3 payments
  11. Other $194 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,382 136 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
Products named General payments · program years 2019–2023
  1. QELBREE $322 26 payments
  2. BRINTELLIX $206 12 payments
  3. REXULTI Psychiatry $189 13 payments
  4. Adzenys XR-ODT $188 14 payments
  5. COTEMPLA XR-ODT $188 14 payments
  6. VRAYLAR $175 11 payments
  7. Trintellix $166 10 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $153 6 payments
  9. JORNAY PM $114 1 payment
  10. REXULTI Psychiatry $103 6 payments
  11. Other $903 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record